Wockhardt Ltd (WOCKPHARMA) - Financial and Strategic SWOT Analysis Review

September 2021 | 49 pages | ID: WF9FF5A3ECCEN
GlobalData

Abstracts

Wockhardt Ltd (WOCKPHARMA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Wockhardt Ltd (Wockhardt) is a pharmaceutical company that manufactures and markets vaccines, active pharmaceutical ingredients, formulations and biosimilars. The company's product portfolio caters to various therapeutic areas including orthopedics, dental care, dermatology, rheumatology, gynecology, pediatrics, cardiology, pain management, nephrology, neurology, and diabetes. It also concentrates its research in new chemical entities (NCE), generics, abbreviated new drug applications (ANDAs), biosimilars, novel drug delivery systems (NDDS). The company operates in India, the US, the UK, Ireland, Dubai, U.A.E. and has market presence in Brazil, France, Russia, Vietnam, Mexico, Philippines, Kenya, Nigeria, Ghana and others. Wockhardt is headquartered in Mumbai, Maharashtra, India.

Wockhardt Ltd Key Recent Developments

Feb 10,2021: UK Government announces COVID-19 vaccination contract extension with Wockhardt
Jan 29,2021: Wockhardt Announces Unaudited Financial Results for the quarter and nine months ended 31st December, 2020
Jan 29,2021: Wockhardt announce Unaudited Financial Results For Quarter And Nine Months Ended 31.12.2020.
Aug 31,2020: Wockhardt announces the appointment of Mr. Akhilesh Gupta on the Board
Aug 03,2020: UK teams up with Wockhardt for vaccine manufacturing services

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Wockhardt Ltd - Key Facts
Wockhardt Ltd - Key Employees
Wockhardt Ltd - Key Employee Biographies
Wockhardt Ltd - Major Products and Services
Wockhardt Ltd - History
Wockhardt Ltd - Company Statement
Wockhardt Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Wockhardt Ltd - Business Description
Geographical Segment: Europe
Performance
Geographical Segment: India
Performance
Geographical Segment: Rest of World and CIS
Performance
Geographical Segment: United States
Performance
R&D Overview
Wockhardt Ltd - Corporate Strategy
Wockhardt Ltd - SWOT Analysis
SWOT Analysis - Overview
Wockhardt Ltd - Strengths
Wockhardt Ltd - Weaknesses
Wockhardt Ltd - Opportunities
Wockhardt Ltd - Threats
Wockhardt Ltd - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Wockhardt Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Wockhardt Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Wockhardt Ltd, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Feb 10, 2021: UK Government announces COVID-19 vaccination contract extension with Wockhardt
Jan 29, 2021: Wockhardt Announces Unaudited Financial Results for the quarter and nine months ended 31st December, 2020
Jan 29, 2021: Wockhardt announce Unaudited Financial Results For Quarter And Nine Months Ended 31.12.2020.
Aug 31, 2020: Wockhardt announces the appointment of Mr. Akhilesh Gupta on the Board
Aug 03, 2020: UK teams up with Wockhardt for vaccine manufacturing services
Aug 03, 2020: Wockhardt announces COVID-19 vaccine partnership with UK Government
May 11, 2020: Wockhardt Financial results: 4th quarter and year ended 31st March, 2020
Feb 13, 2020: Dr Reddy’s to buy some Wockhardt generics units for $259m

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Wockhardt Ltd, Key Facts
Wockhardt Ltd, Key Employees
Wockhardt Ltd, Key Employee Biographies
Wockhardt Ltd, Major Products and Services
Wockhardt Ltd, History
Wockhardt Ltd, Other Locations
Wockhardt Ltd, Subsidiaries
Wockhardt Ltd, Key Competitors
Wockhardt Ltd, Ratios based on current share price
Wockhardt Ltd, Annual Ratios
Wockhardt Ltd, Annual Ratios (Cont...1)
Wockhardt Ltd, Annual Ratios (Cont...2)
Wockhardt Ltd, Interim Ratios
Wockhardt Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Wockhardt Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Wockhardt Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Wockhardt Ltd, Performance Chart (2017 - 2021)
Wockhardt Ltd, Ratio Charts
Wockhardt Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Wockhardt Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021